We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SENS:NASDAQSenseonics Holdings, Inc. Analysis

Data as of 2026-06-07 - not real-time

$6.67

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Senseonics delivered Q1 2026 revenue of $11.7 million, an 85% year‑over‑year jump, pushing its annual revenue growth rate to roughly 71.8% and prompting management to lift the full‑year guidance to $60‑$64 million with a 58% gross margin on the latest quarter. The upbeat commercial rollout of the Eversense 365 system and integration of the U.S. sales organization are the primary catalysts behind this momentum, and analysts have upgraded the upside potential to 106% with a median price target of $14.
On the technical side, the stock trades at $6.67, sitting below the 200‑day SMA of $7.15 but comfortably above the 20‑day SMA of $6.17, while the MACD line remains bullish and the RSI sits at a neutral 55. Volume is on a downtrend and 30‑day volatility is extreme at over 107%, compounded by a high beta of 2.28**, indicating pronounced price swings. Despite weak profitability metrics and a high debt load, the combination of strong revenue growth, expanding margins, and substantial upside in analyst forecasts suggests the stock is currently undervalued but carries elevated risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent revenue beat and margin expansion
  • High short‑term volatility and decreasing volume
  • Price below long‑term SMA indicating bearish bias

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth trajectory and raised 2026 outlook
  • Improving gross margins and expanding market adoption of CGM devices
  • Analyst consensus upside of over 100% with a median target of $14

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑term secular demand for continuous glucose monitoring
  • Potential for profitability as scale reduces cost structure
  • Undervalued valuation relative to growth prospects and target price

Key Metrics & Analysis

Financial Health

Revenue Growth71.80%
Profit Margin-196.03%
P/E Ratio-3.0
ROE-168.27%
ROA-37.68%
Debt/Equity67.77
P/B Ratio4.5
Op. Cash Flow$-59129000
Free Cash Flow$-46501000
Industry P/E27.9

Technical Analysis

TrendBearish
RSI55.7
Support$4.80
Resistance$7.23
MA 20$6.17
MA 50$6.36
MA 200$7.15
MACDBullish
VolumeDecreasing
Fear & Greed Index83.02

Valuation

Target Price$13.80
Upside/Downside106.90%
GradeUndervalued
TypeBlend

Risk Assessment

Beta2.28
Volatility107.50%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.